Quick Answer
Aura Biosciences, Inc. reported Cash And Cash Equivalents At Carrying Value of $59.52 million for the year ending 2025.
- Aura Biosciences, Inc. showed an increase of +87.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Aura Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $11.30 million | Q1 2021: $99.67 million | Q2 2021: $92.20 million | Q3 2021: $81.83 million | Q1 2022: $108.38 million | Q2 2022: $53.85 million | Q3 2022: $61.11 million | Q1 2023: $38.49 million | Q2 2023: $47.73 million | Q3 2023: $55.58 million | Q1 2024: $26.28 million | Q2 2024: $30.08 million | Q3 2024: $25.41 million | Q1 2025: $38.23 million | Q2 2025: $107.37 million | Q3 2025: $47.55 million.
- Over the full 6 years of available data (2020 to 2025), Aura Biosciences, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 242.2%.
- Historical annual values: Fiscal year 2025: $59.52 million | Fiscal year 2024: $31.69 million | Fiscal year 2023: $41.06 million | Fiscal year 2022: $121.58 million | Fiscal year 2021: $149.06 million | Fiscal year 2020: $17.39 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: